<DOC>
	<DOCNO>NCT00850603</DOCNO>
	<brief_summary>The objective trial study administration Menomune vaccine give intradermally low-dose subcutaneously versus standard subcutaneously . This study describe immunogenicity Menomune® - A/C/Y/W-135 administer subcutaneously ( standard dose ) versus intradermally dose range ( 1/10th , 2/10th , 3/10th standard dose ) low dose ( 2/10th standard dose ) subcutaneously . The secondary objective describe safety subcutaneous ( SC ) intradermal ( ID ) rout different dosage</brief_summary>
	<brief_title>Safety Immunogenicity Intradermal Versus Subcutaneous Doses Menomune®</brief_title>
	<detailed_description>This trial provide proof concept dose range Menomune give ID induce immune response comparable standard dose SC route , equivalent superior low dose give SC . Subjects randomize accord computer-generated randomization schedule receive vaccine SC injection ID injection different dosage .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<criteria>Inclusion Criteria : 18 55 year age . Willing return 3 followup visit comply 30 day followup period . Signed informed consent form . Exclusion Criteria : Allergy component vaccine latex . Known suspected immunodeficiency receipt immunosuppressive therapy blood product within previous two month . History serious chronic disease ( cardiac renal disease ) . Acute febrile illness time visit . Pregnancy . Receipt vaccine within 28 day prior enrollment . Receipt meningococcal vaccine ( example Military ) within past 5 year history meningococcal disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Menomune® - A/C/Y/W-135</keyword>
	<keyword>Meningococcal Infections</keyword>
	<keyword>Meningitis</keyword>
</DOC>